Literature DB >> 22927204

Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease.

Lynn M Bekris1, Steve Millard, Franziska Lutz, Gail Li, Doug R Galasko, Martin R Farlow, Joseph F Quinn, Jeffrey A Kaye, James B Leverenz, Debby W Tsuang, Chang-En Yu, Elaine R Peskind.   

Abstract

Alzheimer's disease (AD) is characterized by the presence in the brain of amyloid plaques, consisting predominately of the amyloid β peptide (Aβ), and neurofibrillary tangles, consisting primarily of tau. Hyper-phosphorylated-tau (p-tau) contributes to neuronal damage, and both p-tau and total-tau (t-tau) levels are elevated in AD cerebrospinal fluid (CSF) compared to cognitively normal controls. Our hypothesis was that increased ratios of CSF phosphorylated-tau levels relative to total-tau levels correlate with regulatory region genetic variation of kinase or phosphatase genes biologically associated with the phosphorylation status of tau. Eighteen SNPs located within 5' and 3' regions of 5 kinase and 4 phosphatase genes, as well as two SNPs within regulatory regions of the MAPT gene were chosen for this analysis. The study sample consisted of 101 AD patients and 169 cognitively normal controls. Rs7768046 in the FYN kinase gene and rs913275 in the PPP2R4 phosphatase gene were both associated with CSF p-tau and t-tau levels in AD. These SNPs were also differentially associated with either CSF t-tau (rs7768046) or CSF p-tau (rs913275) relative to t-tau levels in AD compared to controls. These results suggest that rs7768046 and rs913275 both influence CSF tau levels in an AD-associated manner. 2012 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22927204      PMCID: PMC3626266          DOI: 10.1002/ajmg.b.32094

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  39 in total

1.  PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta.

Authors:  Wei Qian; Jianhua Shi; Xiaomin Yin; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 3.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

4.  SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Kevin Mayo; Noah Spiegel; Sarah Bertelsen; Petra Nowotny; Aarti R Shah; Richard Abraham; Paul Hollingworth; Denise Harold; Michael M Owen; Julie Williams; Simon Lovestone; Elaine R Peskind; Ge Li; James B Leverenz; Douglas Galasko; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

5.  Genetic association between -93A/G polymorphism in the Fyn kinase gene and alcohol dependence in Spanish men.

Authors:  Isabel J Pastor; F Javier Laso; Sandra Inés; Miguel Marcos; Rogelio González-Sarmiento
Journal:  Eur Psychiatry       Date:  2008-10-11       Impact factor: 5.361

6.  Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.

Authors:  Lynn M Bekris; Steven P Millard; Nichole M Galloway; Simona Vuletic; John J Albers; Ge Li; Douglas R Galasko; Charles DeCarli; Martin R Farlow; Chris M Clark; Joseph F Quinn; Jeffrey A Kaye; Gerard D Schellenberg; Debby Tsuang; Elaine R Peskind; Chang-En Yu
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

Review 7.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Authors:  Diane P Hanger; Brian H Anderton; Wendy Noble
Journal:  Trends Mol Med       Date:  2009-02-24       Impact factor: 11.951

Review 8.  The microtubule-associated protein tau is also phosphorylated on tyrosine.

Authors:  Thibaud Lebouvier; Timothy M E Scales; Ritchie Williamson; Wendy Noble; Charles Duyckaerts; Diane P Hanger; C Hugh Reynolds; Brian H Anderton; Pascal Derkinderen
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 9.  Tau pathophysiology in neurodegeneration: a tangled issue.

Authors:  Tara L Spires-Jones; William H Stoothoff; Alix de Calignon; Phillip B Jones; Bradley T Hyman
Journal:  Trends Neurosci       Date:  2009-01-21       Impact factor: 13.837

10.  ENCODE whole-genome data in the UCSC Genome Browser.

Authors:  Kate R Rosenbloom; Timothy R Dreszer; Michael Pheasant; Galt P Barber; Laurence R Meyer; Andy Pohl; Brian J Raney; Ting Wang; Angie S Hinrichs; Ann S Zweig; Pauline A Fujita; Katrina Learned; Brooke Rhead; Kayla E Smith; Robert M Kuhn; Donna Karolchik; David Haussler; W James Kent
Journal:  Nucleic Acids Res       Date:  2009-11-17       Impact factor: 16.971

View more
  8 in total

1.  Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease.

Authors:  Jeffrey A Zahratka; Yvonne Shao; McKenzie Shaw; Kaitlin Todd; Shane V Formica; Maria Khrestian; Thomas Montine; James B Leverenz; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2016-11-15       Impact factor: 4.673

2.  Alzheimer's disease risk genes and the age-at-onset phenotype.

Authors:  Madhav Thambisetty; Yang An; Toshiko Tanaka
Journal:  Neurobiol Aging       Date:  2013-07-17       Impact factor: 4.673

3.  Genetic discoveries in AD using CSF amyloid and tau.

Authors:  Carlos Cruchaga; Mark T W Ebbert; John S K Kauwe
Journal:  Curr Genet Med Rep       Date:  2014-03-01

Review 4.  Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

Authors:  Pritam Thapa; Sunil P Upadhyay; William Z Suo; Vikas Singh; Prajwal Gurung; Eung Seok Lee; Ram Sharma; Mukut Sharma
Journal:  Bioorg Chem       Date:  2021-01-29       Impact factor: 5.307

5.  Genes associated with the progression of neurofibrillary tangles in Alzheimer's disease.

Authors:  A Miyashita; H Hatsuta; M Kikuchi; A Nakaya; Y Saito; T Tsukie; N Hara; S Ogishima; N Kitamura; K Akazawa; A Kakita; H Takahashi; S Murayama; Y Ihara; T Ikeuchi; R Kuwano
Journal:  Transl Psychiatry       Date:  2014-06-10       Impact factor: 6.222

Review 6.  Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions.

Authors:  Carmela Matrone; Federica Petrillo; Rosarita Nasso; Gabriella Ferretti
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

7.  Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Authors:  Lyzel S Elias-Sonnenschein; Seppo Helisalmi; Teemu Natunen; Anette Hall; Teemu Paajanen; Sanna-Kaisa Herukka; Marjo Laitinen; Anne M Remes; Anne M Koivisto; Kari M Mattila; Terho Lehtimäki; Frans R J Verhey; Pieter Jelle Visser; Hilkka Soininen; Mikko Hiltunen
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

Review 8.  Fyn kinase inhibition as a novel therapy for Alzheimer's disease.

Authors:  Haakon B Nygaard; Christopher H van Dyck; Stephen M Strittmatter
Journal:  Alzheimers Res Ther       Date:  2014-02-05       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.